CMPS Stock Recent News

Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine as a depression therapeutic.

Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year.

Psychedelics stocks could be buoyed by a few positive events soon. The government is now funding the study of certain psychedelics.

LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference at 10:25 am ET on November 30, 2023.

COMPASS Pathways plc (NASDAQ:CMPS ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Mary-Rose Hughes - Interim CFO Dr. Guy Goodwin - Chief Medical Officer Conference Call Participants Ritu Baral - TD Cohen Charles Duncan - Cantor François Brisebois - Oppenheimer Patrick Trucchio - H.C. Wainright Michael Okunewitch - Maxim Group Sumant Kulkarni - Canaccord Genuity Gavin Clark-Gartner - Evercore ISI Thomas Shrader - BTIG Operator Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Third Quarter 2023 Conference Call.

LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update on recent business developments on November 2, 2023.

Psychedelic stocks are on the rise. Despite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness for treating a variety of conditions.

LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following investor conferences:

Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.

COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Guy Goodwin - Chief Medical Officer Mike Falvey - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen and Company, LLC Charles Duncan - Cantor Fitzgerald Patrick Trucchio - H.C. Wainwright & Co, LLC Francois Brisebois - Oppenheimer & Co. Elemer Piros - EF Hutton Thomas Shrader - BTIG Kyle Qian - Canaccord Genuity Michael Okunewitch - Maxim Group LLC Operator Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Second Quarter 2023 Conference Call.